Main content area

Induction of immune responses by a novel recombinant fusion protein of enterovirus A71 in BALB/c mice

Issaro, Nipatha, Wu, Fenfang, Weng, Lei, Zhou, Mi, Fang, Zhaoxiang, Huang, Sisi, Rajamanickam, Vinothkumar, Liu, Min, Tian, Haishan, Li, Xiaokun, Jiang, Chao
Molecular immunology 2019 v.105 pp. 1-8
CD8-positive T-lymphocytes, Enterovirus A, adjuvants, antibodies, biotechnology, cell culture, gene expression, immune response, immunization, immunoglobulin G, insects, interferon-gamma, interleukin-10, interleukin-2, lymphocyte proliferation, messenger RNA, mice, recombinant fusion proteins, subgenotype, surface proteins, vaccines
Fusion protein technology is used in biotechnology and medical developments. In this study, recombinant fusion proteins from enterovirus A71 (EV-A71) subgenotype B5, Thailand were designed based two surface proteins (VP1 and VP2) and an internal protein (VP4), and named “VP0” (consisting of VP4-VP2) and “EV71” (consisting of VP4-VP2-VP1), respectively. The recombinant fusion proteins VP0 and EV71 were expressed in insect cells and successfully produced and secreted into the media. Both recombinant fusion proteins were shown to have immunogenic properties in BALB/c mice when formulated with Freund’s complete/incomplete adjuvant (FA). Interestingly, EV71 formulated with FA- induced a level of IgG antibodies level similar to that induced by the recombinant protein VP1 formulated with FA (the positive control). Our results showed that VP1 alone is better at eliciting a strong cell-mediated immune response. Nontheless, EV71 formulated with FA was capable of inducing lymphocyte proliferation and increasing the cytokine-related mRNA expression levels of interferon-γ (IFN-γ), interleukin-2 (IL-2), and IL-10 in mice after immunization. Additionally, the number of CD4+ and CD8+ T lymphocyte cells after stimulation with purified EV71 in splenic cell culture showed highly specific CD4+ and CD8+ T-cell production. We suggest that EV71, which consists of VP4-VP2-VP1, could be used as the foundation for developing a novel recombinant fusion protein-based vaccine for EV-A71.